Biomarker Analysis on Ductal Lavage Fluid as a Tool for Breast Cancer Early Detection

Similar documents
// Award Number: DAMD TITLE: Markers of Breast Cancer Risk in Women with Benign Breast Disease PRINCIPAL INVESTIGATOR:

TITLE: Evaluation of DNA Methylation as a Target for Intraductal Therapy for Ductal Carcinoma in Situ of the Breast

TITLE: Dynamic Functional Mammoscopy: A Non-Ionizing Imaging Technique Enhancing Early Detection of Breast Cancer

CONTRACTING ORGANIZATION: University of California Lawrence Berkeley National Laboratory Berkeley, CA 94720

AD (Leave blank) TITLE: Proteomic analyses of nipple fluid for early detection of breast cancer

Detection of Prostate Cancer Progression by Serum DNA Integrity

TITLE: Dietary Genistein and Prostate Cancer Chemoprevention

The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

TITLE: Neural Protein Synuclein (SNCG) in Breast Cancer Progression

TITLE: New Advanced Technology to Improve Prediction and Prevention of Type 1 Diabetes

REPORT DOCUMENTATION PAGE OMB No

TITLE: Outcomes of Screening Mammography in Elderly Women

Keith 0. Plowden, Ph.D. Leonard Derogatis, Ph.D. U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Exploring Early Detection Methods: Using the Intraductal Approach to Predict Breast Cancer

CONTRACTING ORGANIZATION: New York University School of Medicine New York, New York 10016

TITLE: Identification of Chromosomes Alterations in Primary Breast Cancer Using Premature Chromosome Condensation

CONTRACTING ORGANIZATION: Sloan-Kettering Institute for Cancer Research New York, NY 10021

TITLE: Do the Effects of Exercise on Breast Cancer Vary with Environment?

Expression and Promoter Methylation of P16INK4A During Estrogen-Induced Mammary Carcinogenesis in the ACI Rat. Omaha, NE

CONTRACTING ORGANIZATION: North Eastern Ohio Universities Rootstown OH 44202

Jane Teas, Ph.D. University of South Carolina Columbia, South Carolina 29208

Fort Detrick, Maryland

TITLE: Phase I and II Trial of Huanglian, A Novel Botanical Against Breast Cancer That Enhances Taxol Activity. Gary K. Schwartz, M.D.

TITLE: A PSCA Promoter Based Avian Retroviral Transgene Model of Normal and Malignant Prostate

A Randomized Placebo-Controlled Trial of Citalopram for Anxiety Disorders Following Traumatic Brain Injury

AWARD NUMBER: W81XWH TITLE: Treatment of Pain and Autonomic Dysreflexia in Spinal Cord Injury with Deep Brain Stimulation

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

CONTRACTING ORGANIZATION: The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AWARD NUMBER: W81XWH TITLE: Gulf War Illness as a Brain Autoimmune Disorder. PRINCIPAL INVESTIGATOR: Apostolos Georgopoulos, MD, PhD

Award Number: W81XWH

TITLE: 64Cu-DOTA-trastuzumab PET imaging in women with HER2 overexpressing breast cancer

CONTRACTING ORGANIZATION: Vanderbilt University Medical Center Nashville, TN

CONTRACTING ORGANIZATION: Western Institute For Biomedical Research Salt Lake City, UT

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: The Role of hcdc4 as a Tumor Suppressor Gene in Genomic Instability Underlying Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Approved for Public Release; Distribution Unlimited

TITLE: Characterization of the Mechanisms of IGF-I-Mediated Stress-Activated Protein Kinase Activation in Human Breast Cancer Cell MCF-7

TITLE: Prostate Expression Databases: Gene Expression Resources for Comparative Studies of Prostate Carcinogenesis

La Jolla, CA Approved for Public Release; Distribution Unlimited

Approved for public release; distribution unlimited

TITLE: Identification of New Serum Biomarkers for Early Breast Cancer Diagnosis and Prognosis Using Lipid Microarrays.

TITLE: Autocrine and Paracrine Control of Breast Cancer Growth by Sex Hormone-Binding Globulin

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Deborah Watkins-Bruner, Ph.D. Fox Chase Cancer Center Philadelphia, Pennsylvania 19111

CONTRACTING ORGANIZATION: Johns Hopkins Bloomberg School of Public Health

CONTRACTING ORGANIZATION: UNIVERSITY OF ILLINOIS Chicago, IL 60612

TITLE: Enhancing the Anti-Tumor Activity of ErbB Blockers with Histone Deaccetylase (HDAC) Inhibition in Prostate Cancer Cell Lines

TITLE: The Prospective Army Coronary Calcium (PAAC) Study

TITLE: Estrogen-DNA Adducts as Novel Biomarkers for Ovarian Cancer Risk and for Use in Prevention

CONTRACTING ORGANIZATION: Cold Spring Harbor Laboratory Cold Spring Harbor, NY 11724

CONTRACTING ORGANIZATION: Evanston Northwestern Healthcare Research Institute

TITLE: Genes Associated with Food Allergy and Eosinophilic Esophagitis

TITLE: MicroRNA in Prostate Cancer Racial Disparities and Aggressiveness

Award Number: W81XWH TITLE: Characterizing an EMT Signature in Breast Cancer. PRINCIPAL INVESTIGATOR: Melanie C.

TITLE: Role of Estrogen Metabolism in the Initiation of Prostate Cancer: Biomarkers of Susceptibility and Early Detection

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Long Term Outcomes of BRCA1/BRCA2 Mutation Testing. CONTRACTING ORGANIZATION: Georgetown University Washington, DC

TITLE: Computerized Tailored Interventions for Behavioral Sequelae of Post-Traumatic Stress Disorder in Veterans

Award Number: W81XWH TITLE: Dietary Fish Oil in Reducing Bone Metastasis of Breast Cancer

TITLE: Adipose Estrogen and Increased Breast Cancer Risk in Obesity: Regulation by Leptin and Insulin

CONTRACTING ORGANIZATION: Regents of the University of Michigan Ann Arbor, MI 48109

Targeting Stromal Recruitment by Prostate Cancer Cells

CONTRACTING ORGANIZATION: The Chancellor, Masters and Scholars of the University of Cambridge, Clara East, The Old Schools, Cambridge CB2 1TN

TITLE: Investigation of the Akt/PKB Kinase in the Development of Hormone-Independent Prostate Cancer

TITLE: Selective Oncolytic Therapy for Hypoxic Breast Cancer Cells. CONTRACTING ORGANIZATION: Ordway Research Institute Albany, New York 12208

TITLE: Oxidative Stress, DNA Repair and Prostate Cancer Risk. PRINCIPAL INVESTIGATOR: Hua Zhao, Ph.D.

CONTRACTING ORGANIZATION: Oregon Health & Science University Portland OR 97239

CONTRACTING ORGANIZATION: Mount Sinai School of Medicine New York, New York

Award Number: W81XWH TITLE: CYP1B1 Polymorphism as a Risk Factor for Race-Related Prostate Cancer

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

AD (Leave blank) Award Number: W81XWH TITLE: Targeting Autophagy for the Treatment of TSC and LAM. PRINCIPAL INVESTIGATOR: Elizabeth Henske

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Sphingosine-1-Phosphate Receptor Subtype 3: A Novel Therapeutic Target of K-Ras Mutant Driven Non-Small Cell Lung Carcinoma

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

Co-PI: Amy Trentham-Dietz, PhD

TITLE: Effect of Reminder Telephone Calls on Mammography Compliance in High Risk

TITLE: Anti-Angiogenic Gene Therapy of Prostate Cancer with Lentiviral Vectors

TITLE: Induction of Ephs/Ephrins-Mediated Tumor Cells-Endothelial Cells Repulsion as an Anti-Cancer Therapeutic Approach

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: HER2/neu Antisense Therapeutics in Human Breast Cancer. CONTRACTING ORGANIZATION: Washington University School of Medicine St.

TITLE: The Role of HOX Proteins in Androgen-Independent Prostate Cancer

Roles of microrna-mediated Drug Resistance in Tumor Stem Cells of Small Cell Lung Carcinoma

TITLE: Reduction of Radiation- or Chemotherapy-Induced Toxicity by Specific Expression of Anti-Apoptotic Molecules in Normal Cells

TITLE: Development of a Blood-Based Biomarker Panel for Indeterminate Lung Nodules

TITLE: Proteomic Mapping of the Immune Response to Gluten in Children with Autism

Award Number: MIPR 3GD3DN3081. TITLE: Outcomes of Telehealth Group Psychosocial Interventions for Breast Cancer Patients and Their Partners

Award Number: W81XWH

New York, New York U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland

TITLE: Prevention and Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors

TITLE: Tumor Specific CD4+ T-Cell Costimulation Through a Novel Receptor/Ligand Interaction

TITLE: Breast Density Assessment by Dual Energy X-ray Absorptiometry in Women and Girls. Rachel Novotny, Ph.D. Honolulu, HI 96822

Award Number: W81XWH TITLE: Global Positioning Systems (GPS) Technology to Study Vector-Pathogen-Host Interactions

PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland X Approved for public release; distribution unlimited

Award Number: W81XWH TITLE: A Novel Membrane-Permeable, Breast-Targeting, Pro-Apoptotic Peptide for Treatment of Breast Cancer

Transcription:

AD Award Number: DAMD17-01-1-0495 TITLE: Biomarker Analysis on Ductal Lavage Fluid as a Tool for Breast Cancer Early Detection PRINCIPAL INVESTIGATOR: Jian Yu Rao, M.D. Wei Zhang, M.D. BaoNing Zhang, M.D. Qinjing Pan, M.D. Karen Duvall, M.D. Mai Nguyen Brook, M.D. CONTRACTING ORGANIZATION: University of California at Los Angeles Los Angeles, California 90024-1604 REPORT DATE: October 2002 TYPE OF REPORT: Final PREPARED FOR: U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. 20030319 055

Form Approved REPORT DOCUMENTATION PAGE [MB No. 074-0188 Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503 1. AGENCY USE ONLY (Leave blank) 2. REPORT DATE 3. REPORT TYPE AND DATES COVERED October 2002 Final (17 Sep 01-16 Sep 02) 4. TITLE AND SUBTITLE 5. FUNDING NUMBERS Biomarker Analysis on Ductal Lavage Fluid as a Tool for Breast Cancer Early Detection 6. AUTHOR(S): Jian Yu Rao, M.D., Wei Zhang, M.D., BaoNing Zhang, M.D., Qinjing Pan, M.D., Karen Duvall, M.D., Mai Nguyen Brook, M.D. DAMD17-01-1-0495 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBER University of California at Los Angeles Los Angeles, California 90024-1604 E-Mail: JRAO@MEDNET.UCLA.EDU 9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSORING / MONITORING AGENCY REPORT NUMBER U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012 11. SUPPLEMENTARY NOTES 12a. DISTRIBUTION / AVAILABILITY STATEMENT 12b. DISTRIBUTION CODE Approved for Public Release; Distribution Unlimited 13. Abstract (Maximum 200 Words) (abstract should contain no proprietary or confidential information) The current breast cancer diagnostic methods rely on identification of the tumor mass and therefore have limited success for detecting early lesions in which preventive measures could effectively be carried out. We propose a novel approach using ductal lavage technique, coupled with biomarker profile analysis on the fluid and cells obtained. This approach facilitates the detection of malignant or premalignant lesions in individuals who have undetectable tumor masses. We hypothesis that the development of breast cancer is preceded by molecular field disease changes, and therefore cells obtained from any area of the duct will signal the biochemical and molecular changes associated with carcinogenesis. To test this hypothesis, we first performed a molecular mapping study. Ductal epithelial cells obtained from cancereous and non-cancerous ducts were collected from several mastectomy samples. Molecular analysis including analysis of proliferation marker Ki67 and methylation of RAR-B were performed. The results showed that lavaged ducts as well as adjacent non-canerous duct epithelial cells shared similar molecular abnormalities to the cancerous duct epithelial cells. This finding provided direct support for the field disease concept of breast cancer carcinogenesis and further substantiate the ductal lavage technique as an approach for breast cancer early detection. In our pilot study, ductal lavage was performed on contralateral noncancer breast for 3 patient with newly diagnosed breast cancer, 10 patients with atypical breast lesions with nipple discharge, 9 patients with benign breast lesions without nipple discharge, and 19 healthy female with family history of breast cancer in both Chinese women and American women. The results showed that ductal lavage was capable of detecting abnormal cells from high risk individuals without clinically identifiable lesions, thus provided a means for early detection. Further studies are needed to confirm the observation. 14. SUBJECT TERMS 15. NUMBER OF PAGES breast cancer, ductal lavage fluid, Ki67 7 16. PRICE CODE 17. SECURITY CLASSIFICATION 18. SECURITY CLASSIFICATION 19. SECURITY CLASSIFICATION 20. LIMITATION OF ABSTRACT OF REPORT OF THIS PAGE OF ABSTRACT Unclassified Unclassified Unclassified Unlimited NSN 7540-01-280-5500 Standard Form 298 (Rev. 2-89) Prescribed by ANSI Std. Z39-18 298-102

Table of Contents C over... 1 SF 298... 2 Table of Contents... 3 Introduction... 4 Body... 5 Key Research Accomplishments... 6 Reportable Outcomes... 6 Conclusions... 6 References... 6 Appendices... 3

INTRODUCTION The current breast cancer diagnostic methods rely on identification of the tumor mass, and therefore have limited value for detecting early lesions in which preventive measures could effectively be carried out. Unlike other solid organs, the human female breast consists of mostly fatty tissue, and random sampling using fine needle aspiration or core biopsy for a unpalpable, even a radiological or clinically suspected lesion, is usually unrevealing.' Techniques that can directly obtain cells from the duct epithelial cells (which are the cells of most of breast cancers originated from) and methods that can analyze multiple biomarkers on small volume basis are therefore urgently needed. Recently two emerging techniques, the ductal canalization and Biomarker Profile Analysis, have been developed exactly for such purposes. This study is designed to test the feasibility of combining these two techniques together and determine preliminary whether such an approach provides a more accurate screening test to detect earlier breast lesions than the existing mammogram technique. The duct lavage technique developed by ProDuct Health, Inc. allows the sampling of cells from a specific area of the breast duct, and is highly efficient in obtaining cells for analysis. 2 The Biomarker Profile Analysis is an approach developed in our laboratory. This method enables the analysis of multiple phenotypic and genotypic biomarkers on a small sample volume basis, without the need to compromise the conventional cytomorphologic analysis. 3 ' 4 However, since each breast contains 7 to 12 ducts, and it is unrealistic to canalize all the ducts in clinical setting, it is crucial to determine whether specific molecular changes associated with breast cancer can be detected in the "field". And if so, then biomarker profile analysis on cells obtained from one the field might provide information to determine whether there is an early malignancy elsewhere. Therefore an additional purpose of this pilot study is to test such "field" hypothesis. This study was carried out in small groups of women who have various risks of developing breast cancer. The studies will be performed in Chinese women in Beijing, China and American women in Los Angeles. The recent rapid increase of breast cancer incidence in Chinese women provides a unique opportunity to study the biology of breast cancer development. The rational to involve Chinese women in China is mainly because the ductal lavage device has not been tested in Asian women, including Chinese women, and in addition we would like to test the feasibility of conducting such study in China. The ultimate goal of this project is to develop a simple, minimally invasive, and accurate screening method for breast cancer. The immediate objective of this project is to determine the feasibility of performing ductal lavage analysis in women with different racial and social environmental backgrounds, and study preliminary the values of such an approach in breast cancer early detection. 4

BODY Specific Aims: There were two specific aims in this pilot study: 1. To perform a molecular mapping analysis to further validate ductal lavage approach and to identify novel molecular markers 2. To perform lavage in both Chinese and American women, to test the feasibility of performing ductal lavage in women with different ethnic and social background Results: For specific aim #1, mastectomy specimens were used to obtain ductal epithelial cells by microdissection from lavaged ducts, adjacent non-cancerous ducts, and cancerous ducts. Markers analyzed included Ki67 by immunohistochemistry and RAR-beta by methylaiton specific PCR. RAR-beta is a marker for cellular differentiation and a tumor suppresser gene while loss of function seen in breast cancer, primarily by mechanisms of DNA hypermethylation and LOH. Methylation of RAR-beta-2 can be detected in ductal fluid obtained by ductal lavage technique. 5 As shown in Figure 1 below, our study demonstrated taht methylation of RAR-beta gene promoter, but not Ki67 over expression can be seen in not only the cancer cells, but also adjacent non-cancerous ductal epithelial cells and lavaged ductal epithelial cells. This finding supports our hypothesis that cancer associated molecular "field defect" can be detected in non-cancerous ductal epithelial cells, thus may be potential biomarkers for breast cancer risk. Figure 1: RESULTS OF MOLECULAR MAPPING ANALYSIS KW67 - +++ +/- RAR-beta MW N P LD A2 A6 T A7 u M u m u m u m u m u m u m MW - Molecular Weight N - Negative (lymphocytes) P - Positive (MCF cells) LD - Ductal Lavaged sample A2/6/7 - Areas of non-tumor T- Tumor U - Unmethylated M - Methylated Conclusion: Methylation of RAR-beta gene promoter, but not Ki67 over expression can be seen In not only the cancer cells, but adjacent non-cancerous ductal epithelial cells and lavaged ductal epithelial cells For Specific Aim #2, a pilot study was performed in both Chinese and American Women. The study groups were: In Cancer Institute/CAMS, China: 1. Contralateral non-cancer breast for 3 patient with newly diagnosed breast cancer 2. 10 patients with atypical breast lesions with nipple discharge 3. 9 patients with atypical breast lesions without nipple discharge In UCLA: 4. 19 healthy female with family history of breast cancer. 5

Cytological analysis was performed on Thin prep slides, and the results were presented in following table: Overall our preliminary study showed that cytological analysis of ductal lavage samples correlated well with breast cancer risk. Severe cytological atypia was detected in the contralateral breast in one of three breast cancer patients, and 1 of 10 patients with atypical breast lesions (with atypical ductal hyperplasia to atypical lobular hyperplasia), but none in women with benign breast lesions (fibroadenoma) and healthy individuals but with positive family history. Study #2: Ductal lavage analysis in subjects with various risk of developing breast cancer - Results of a pilot stud_ Subject Group n Attempted Succesfully Cytological Findings Lavaged Ducts Lavaged Ducts 1.Contralateral breast 3 5 4 1 - Severe atypia in newly dig. breast 2 - Mild atypia ca patient 1 - Negative 2. Atypical breast 10 10 10 1- Severe atypia lesion with nipple 6 - Mild atypia discharge* 3 - Negative 3. Benign breast 9 9 5 1- Mild atypia lesions without nipple 4- Negative discharge I 4. Healthy individual 19 24 13 1-Mild atypia with family history 12- Negative KEY RESEARCH ACCOMPLISHMENTS 1. IRB approval from all levels 2. Both video and in person training for performing ductal lavage in Cancer Institute/CAMS, China 3. Experience gained from mastectomy specimen before live patient 4. Provided further molecular evidence to support ductal lavage approach 5. Demonstrated the feasibility of ductal lavage procedures in women with different ethnic and social environmental backgrounds 6. Molecular based analysis, including QFIA analysis as proposed, of collected material is still ongoing REPORTABLE OUTCOMES 1. Cytological analysis of ductal lavage fluid from women with various risk of developing breast cancer CONCLUSIONS 1. Ductal lavage provides an useful alternative approach for early detection of breast cancer 2. Feasibility to perform international collaborative ductal lavage study is demonstrated 3. Additional studies will be needed to determine the value of biomarker analysis in lavage samples REFERENCES 'Salami, N, Hirschowitz, S, Nieberg, R, Apple, S. Triple test approach to inadequate fine needle aspiration biopsies of palpable breast lesions. Acta Cytologica, 43(3):339-43, 1999. 2 Love, SM; Barsky, SH. Breast-duct endoscopy to study stages of cancerous breast disease. Lancet, 348(9033):997-9, 1996. 3 Rao, JY, Apple, S, Jin, YS, Hemstreet, GP, and Nieberg, R. Single cell multiple biomarker analysis in archival Fine Needle Aspiration specimens: Quantitative Fluorescence Image Analysis of DNA ploidy, p53 and G-actin as breast cancer biomarkers. Cancer Epidemiology, Biomarkers and Prevention, 7(11)1027-1033, 1998. 4 Rao, JY, Apple, S, Jin YS, et al. Comparative PCR analysis of c-myc amplification on archival breast fine needle aspiration (FNA) materials. Cancer Epidemiology, Biomarkers and Prevention. 9:175-179, 2000. 6

5 Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, Soito AB, Hung DT, Ljung B, Davidson NE, Sukumar S. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet. 28;357(9265):1335-6, 2001.